Abstract
ObjectivesAliskiren is a novel renin-angiotensinaldosterone system (RAAS) inhibitor, the combination therapy of aliskiren andamlodipine for blood pressure control have been reported recently. The primary objective of this analysis is to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have